

OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Patricio H. Contreras

☑ pathomero@gmail.com

RECEIVED 29 September 2025 ACCEPTED 30 September 2025 PUBLISHED 06 October 2025

CITATION

Contreras PH and Falhammar H (2025) Correction: CRF1 and ACTH inhibitors are a promising approach to treat obesity and leptin and insulin resistance. *Front. Endocrinol.* 16:1715691. doi: 10.3389/fendo.2025.1715691

COPYRIGHT

© 2025 Contreras and Falhammar. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Correction: CRF1 and ACTH inhibitors are a promising approach to treat obesity and leptin and insulin resistance

Patricio H. Contreras (b)1* and Henrik Falhammar (b)2,3

¹Reproductive Health Research Institute, Santiago, Chile, ²Department of Endocrinology, Karolinska University Hospital, Stockholm, Sweden, ³Department of Molecular Medicine, Karolinska Institutet, Stockholm, Sweden

KEYWORDS

crinecerfont, atumelnant, leptin resistance, insulin resistance, ACTH inhibitors, hypercortisolism, CRF1 inhibitors

A Correction on

CRF1 and ACTH inhibitors are a promising approach to treat obesity and leptin and insulin resistance

By Contreras PH and Falhammar H (2025). *Front. Endocrinol.* 16:1647028. doi: 10.3389/fendo.2025.1647028

"Affiliation Reproductive Health Research Institute, Santiago, Chile" was erroneously given as "Reproductive Endocrinology Unit, Santiago, Chile".

The original version of this article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.